大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局两大核心药物打开增长空间

智通财经07-08

7月8日，摩根士丹利发布研报，对福泰制药(VRTX.US)以100亿美元收购Crinetics(CRNX.US)的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。福泰制药在新闻稿中表示，扣除收购获得的现金后，该交易对Crinetics的估值为88亿美元，并将提升2029年的调整后...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2649299398?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c","is_english":false,"pubTime":"2026-07-08 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649299398","market":"us","top_or_hot":-1,"title":"大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间","media":"智通财经","content":"<div>\n<p>7月8日，摩根士丹利发布研报，对福泰制药(VRTX.US)以100亿美元收购Crinetics(CRNX.US)的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。福泰制药在新闻稿中表示，扣除收购获得的现金后，该交易对Crinetics的估值为88亿美元，并将提升2029年的调整后...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1464871.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 20:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1464871.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月8日，摩根士丹利发布研报，对福泰制药(VRTX.US)以100亿美元收购Crinetics(CRNX.US)的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。福泰制药在新闻稿中表示，扣除收购获得的现金后，该交易对Crinetics的估值为88亿美元，并将提升2029年的调整后...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1464871.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0267386448.USD","symbol_name":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1464871.html","article_id":"2649299398","we_media_id":null,"thumbnails":["https://community-static.tradeup.com/news/7870ada20f73cf52a4a0efa576cd369c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649299398","pubTimestamp":1783512080,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"摩根士丹利发布研报，对福泰制药以100亿美元收购Crinetics的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。值得注意的是，摩根士丹利担任福泰制药的财务顾问，协助该公司达成收购Crinetics的协议。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4139":"生物科技","SG9999001176.USD":"United Global Healthcare Acc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","VRTX":"福泰制药","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2487616109.SGD":"JPM AMERICA EQUITY \"A\" (SGD) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IAI":"iShares Dow Jones U.S. Broker De","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4581":"高盛持仓","BBH":"VanEck Biotech ETF","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0210528500.USD":"JPM AMERICA EQUITY \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4588":"碎股","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IDNA":"iShares Genomics Immunology and Healthcare ETF","LU0079474960.USD":"联博美国增长基金A","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IBB":"生物科技指数ETF-iShares Nasdaq","KBWB":"银行ETF-PowerShares","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IBBQ":"Invesco Nasdaq Biotechnology ETF","BIB":"Ultra纳斯达克生物科","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H"},"translate_title":"Morgan Stanley Interpretation of Futai Pharmaceutical's Ten Billion Acquisition of Crinetics: Complete the Endocrine Pipeline Layout, Two Core Drugs Open Growth Space","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/976f62880929244fb931c575d00a2414","symbols_score_info":{"BBH":0.6,"IBB":0.6,"IAI":0.6,"IBBQ":0.6,"KBWB":0.6,"PBE":0.6,"VRTX":2.1,"IDNA":0.6,"BIB":0.6},"content_text":"7月8日，摩根士丹利发布研报，对福泰制药(VRTX.US)以100亿美元收购Crinetics(CRNX.US)的交易进行解读。此次收购将为福泰制药新增第五大业务支柱——内分泌药物，补齐公司管线布局。根据公告，每股85美元的收购价格较Crinetics周一的收盘价溢价了102%。福泰制药在新闻稿中表示，扣除收购获得的现金后，该交易对Crinetics的估值为88亿美元，并将提升2029年的调整后营业收入。这是福泰制药历史上规模最大的一笔交易。交易预计于2026年第三季度完成。摩根士丹利团队预测，Crinetics在2027年和2030年的营收分别为1.83亿美元和8.3亿美元，分别约占福泰制药总营收的1%和4%。收购核心管线资产价值拆解摩根士丹利指出，Crinetics拥有两款针对罕见内分泌疾病的关键资产：刚上市的肢端肥大症口服治疗药物Palsonify(帕妥索汀);以及促肾上腺皮质激素(ACTH)受体口服拮抗剂Atumelnant，该药物针对先天性肾上腺皮质增生症(CAH)的研究处于3期临床阶段，针对促肾上腺皮质激素依赖性库欣综合征(ADCS)的研究处于2期临床阶段。叠加福泰制药自研1型糖尿病干细胞药物zimislecel，构建完整罕见内分泌管线矩阵。福泰制药表示，Crinetics关键药物的总销售额有望超过50亿美元，其中Palsonify将在收购完成后立即贡献收入增长，而Atumelnant仅CAH适应症就有望创造数十亿美元，同时在ADCS领域具备额外业绩增长空间。摩根士丹利团队预测，到2035年，Palsonify用于肢端肥大症适应症经风险调整后的销售额将达10亿美元。摩根士丹利认为，肢端肥大症属于孤儿药适应症，因此Palsonify可豁免2026年4月公布的美国关税相关规定。Palsonify同时开展类癌综合征适应症的三期临床试验，但这并非此次收购交易的重点。摩根士丹利团队还预测，Atumelnant用于CAH适应症经风险调整后的销售峰值约5亿美元。ADCS适应症方面，美国患病群体超1万人，海外患者约1.5万人。值得注意的是，摩根士丹利担任福泰制药的财务顾问，协助该公司达成收购Crinetics的协议。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649299398","isCrawlerRequest":true}

大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局 两大核心药物打开增长空间

精彩评论

大摩解读福泰制药百亿收购Crinetics：补齐内分泌管线布局两大核心药物打开增长空间